Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia
This Research Article, published in Future Oncology, provides a detailed comparison of zanubrutinib and acalabrutinib for relapsed/refractory chronic…